Package Leaflet: Information for the User
BOTOX 50 Units Allergan, Powder for Solution for Injection
BOTOX 100 Units Allergan, Powder for Solution for Injection
BOTOX 200 Units Allergan, Powder for Solution for Injection
Botulinum toxin type A
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
Contents of the pack
BOTOX is a muscle relaxant used to treat various conditions in the body. It contains the active substance botulinum toxin type A and is injected into the muscles, the bladder wall, or into the skin. It works by partially blocking the nerve impulses to the injected muscles and reducing excessive contractions of these muscles.
When injected into the skin, BOTOX acts on the sweat glands to reduce the amount of sweat produced.
When injected into the bladder wall, BOTOX acts on the bladder muscle to reduce urine loss (urinary incontinence). In the case of chronic migraine, it is believed that BOTOX may block pain signals, indirectly blocking the onset of a migraine. However, the exact way BOTOX works in chronic migraine is not fully understood.
Chronic migraine is a condition that affects the nervous system. Patients usually experience headache pain, which is often accompanied by excessive sensitivity to light, noise, or smells, as well as nausea, vomiting, or both. These headaches occur on 15 or more daysper month.
Do not use BOTOX:
Warnings and precautions
Tell your doctor or pharmacist before using BOTOX:
After being injected with BOTOX
You or your caregiver should go to your doctorand seek medical attention immediately if you experience any of the following symptoms:
General precautions
As with any injection, it is possible that after the procedure you may experience infection, pain, inflammation, abnormal skin sensations (such as tingling or numbness), reduced skin sensation, pain when touching, redness, bleeding/bruising at the injection site, and a drop in blood pressure or fainting: this may be a consequence of the pain and/or anxiety associated with the injection.
Adverse reactions possibly related to the spread of botulinum toxin from the site of administration (such as muscle weakness, difficulty swallowing, or unintended passage of food or liquid into the airways) have been reported with botulinum toxin. These side effects can be mild to severe, may require treatment, and in some cases, can be fatal. This risk is more pronounced for patients with underlying conditions that make them more susceptible to these symptoms.
Severe and/or immediate allergic reactions have been reported, whose symptoms may include hives, inflammation of the face or throat, shortness of breath, wheezing, or fainting. Delayed allergic reactions (serum sickness) have also been reported, which may include symptoms such as fever, joint pain, and skin rash.
Cardiovascular system-related adverse effects, including irregular heartbeat and heart attack, have been reported in patients treated with BOTOX, sometimes with a fatal outcome. However, some of these patients had a history of cardiac risk factors.
Seizures have been reported in adults and children treated with BOTOX, mostly in patients with a predisposition to seizures. It is not known whether BOTOX can cause these seizures. The seizures reported in children occurred mostly in patients with cerebral palsy being treated for persistent muscle spasms.
If you are given BOTOX too frequently or in high doses, you may experience muscle weakness and adverse reactions related to the spread of the toxin, or your body may start producing some antibodies that can reduce the effect of BOTOX.
When BOTOX is used to treat a condition that is not included in this leaflet, it may lead to serious reactions, especially in patients who have difficulty swallowing or significant weakness.
If you have not exercised much for a long time before receiving treatment with BOTOX, you should start some activity gradually after the injections.
It is unlikely that this medicine will improve the range of motion of joints where the surrounding muscle has lost its ability to stretch.
BOTOX should not be used to treat persistent muscle spasms of the ankle due to stroke in adults if it is not expected to improve function (e.g., walking) or symptoms (e.g., pain), or facilitate patient care. If you had a stroke more than 2 years ago or if the muscle spasm in the ankle is less severe, the improvement related to activities such as walking may be limited. Also, your doctor will determine if this treatment is suitable for patients who are more likely to fall.
BOTOX should only be used to treat muscle spasms in the ankle and foot due to stroke after evaluation by healthcare professionals with experience in the management of post-stroke rehabilitation patients.
When BOTOX is used to treat severe muscle spasms in the eyelid, it may cause you to blink less often, which can damage the surface of your eyes. To prevent this, you may need treatment with eye drops, ointments, soft contact lenses, or even a protective cover that closes your eyes. Your doctor will tell you if this is necessary.
When BOTOX is used to control urine loss, your doctor will give you antibiotics before and after treatment to prevent urinary tract infections.
You will have an appointment with your doctor about 2 weeks after the injection, if you did not use a catheter before the injection. You will be asked to urinate and then the amount of urine left in your bladder will be measured by ultrasound. Your doctor will decide if you need to come back for a repeat of this test during the following 12 weeks. You should contact your doctor if at any time you are unable to urinate, as you may need a catheter. In patients with urine loss due to bladder problems associated with spinal cord injury or multiple sclerosis, about one-third of patients who did not use a catheter before treatment may need one after treatment. In patients with urine loss due to overactive bladder, about 6 out of 100 patients may need to use a catheter after treatment.
Using BOTOX with other medicines:
Tell your doctoror pharmacist if:
? you are taking any antibiotic(used to treat infections), anticholinesterases, or . Some of these medicines may increase the effect of BOTOX;
? you have recently been injected with a medicine that contains a botulinum toxin(the active ingredient of BOTOX), as this may greatly increase the effect of BOTOX;
? you are taking any antiplatelet agent (medicines like aspirin) and/or anticoagulants (medicines that make the blood more fluid).
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
The use of BOTOX is not recommended during pregnancy or in women of childbearing age who are not using contraception unless it is absolutely necessary. BOTOX is not recommended in breastfeeding women.
If you are pregnant, breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
BOTOX may cause dizziness, drowsiness, fatigue, or vision problems. If you experience any of these effects, do not drive or use machines. If you are unsure, ask your doctor for advice.
This medicine contains less than 1 mmol of sodium (23 mg) per vial; this is essentially "sodium-free".
BOTOX should only be injected by doctors with specific skills and experience in using this medication.
BOTOX should only be prescribed for your chronic migraine if you have been diagnosed by a neurologist who is a specialist in this field. BOTOX must be administered under the supervision of a neurologist. BOTOX is not used for acute migraine, chronic tension-type headaches, or for patients with headache due to excessive use of medications.
Method and route of administration
BOTOX is injected into the muscles (intramuscularly), into the bladder wall using a specific instrument (cystoscope) for injection into the bladder, or into the skin (intradermally). It is injected directly into the affected area of your body; your doctor will normally inject BOTOX into several sites within each affected area.
General dosing information
The dose of BOTOX and the duration of its effect will vary depending on the disease for which it is being treated. The following details are specific to each disease.
The safety and efficacy of BOTOX have been established in children/adolescents over 2 years of age for the treatment of persistent muscle spasms in the ankle and foot associated with cerebral palsy.
There is limited information on the use of BOTOX for the following indications in children/adolescents over the ages listed in the following table. No dosage recommendation can be made for these indications.
Persistent muscle spasms in the eyelid and face | 12 years |
Persistent muscle spasms in the neck and shoulder | 12 years |
Excessive sweating of the armpits | 12 years (limited experience in adolescents between 12 and 17 years of age) |
Neurogenic overactive bladder in pediatrics | 5-17 years |
Overactive bladder in pediatrics | 12-17 years |
Dosage
The dosing of BOTOX and the duration of its effect will vary depending on the condition for which you are being treated. The following details are specific to each condition.
Indication | Maximum dose (Units per affected area) | Minimum time between treatments | |
First treatment | Subsequent treatments | ||
Persistent muscle spasms in ankle and foot in children with cerebral palsy | Ankle and foot:4 to 8 Units/kg or 300 Units, whichever is lower | When treating ankle and foot in both legs, the maximum dose should not exceed 10 Units/kg or 340 Units, whichever is lower | 12 weeks* |
Persistent muscle spasms in the wrist and hand of adult patients who have had a stroke | The exact dose and number of injections per wrist/hand are individualized according to individual needs up to a maximum of 240 Units. | The exact dose and number of injections are individualized according to individual needs up to a maximum of 240 Units. | 12 weeks |
Persistent muscle spasms in the ankle and foot of adult patients who have had a stroke | Your doctor may administer multiple injections into the affected muscles. The total dose is 300 Units to 400 Units divided among up to 6 muscles for each treatment session | The total dose is 300 Units to 400 Units divided among up to 6 muscles for each treatment session | 12 weeks |
Persistent muscle spasms in eyelids and face | 1.25-2.5 Units per injection point Up to 25 Units per eye for eye spasms | Up to 100 Units for eye spasms | 3 months for eye spasms |
Persistent muscle spasms in neck and shoulders | 200 Units No more than 50 Units should be administered per injection point | Up to 300 Units | 10 weeks |
Headache in adult patients with chronic migraine | 155 to 195 Units No more than 5 Units should be administered per injection point | 155 to 195 Units | 12 weeks |
Overactive bladder with urine loss | 100 Units | 100 Units | 3 months |
Urinary incontinence due to bladder problems associated with spinal cord injury or multiple sclerosis in adult patients | 200 Units | 200 Units | 3 months |
Excessive sweating of the armpits | 50 Units per armpit | 50 Units per armpit | 16 weeks |
Time to Improvement and Duration of Effect
For persistent muscle spasms in ankle and foot in children 2 years of age or older,improvement will normally appear during the first 2 weeks following injection
For persistent muscle spasms in the wrist and hand of adult patients who have had a stroke,you will normally notice improvement during the 2 weeks following injection. The maximum effect is generally observed 4 to 6 weeks after treatment.
For persistent muscle spasms in the ankle and foot of adult patients who have had a stroke, you may receive treatment again if necessary when the effect starts to disappear, although no more frequently than every 12 weeks.
For persistent muscle spasms in eyelids and face,you will normally see improvement within 3 days after injection and the maximum effect is normally seen after 1 or 2 weeks.
For muscle spasms in neck and shoulders,you will generally notice improvement during the 2 weeks following injection. The maximum effect is normally seen 6 weeks after treatment.
For urinary incontinence due to overactive bladder,you will normally observe improvement in the first 2 weeks after injection. The effect usually lasts approximately 6-7 months after injection.
For urinary incontinence due to bladder problems associated with spinal cord injury or multiple sclerosis,you will normally observe improvement in the first 2 weeks after injection. The effect usually lasts approximately 8-9 months after injection.
For excessive sweating of the armpits, you will normally notice improvement during the first week after injection. The effect normally lasts, on average, 7.5 months after the first injection, and approximately 1 in 4 patients still show the effect after 1 year.
If you have received more BOTOX than you should
Signs of excess BOTOX may not appear immediately after injection. If you ingest BOTOX or it is accidentally injected, you should consult your doctor, who should keep you under observation for several weeks.
If you have received too much BOTOX, you may experience some of the following symptoms and should contact your doctor immediately. He/she will decide if you should go to the hospital:
If you have any additional questions about the use of this product, ask your doctor or pharmacist.
IF YOU EXPERIENCE ANY DIFFICULTY BREATHING, SWALLOWING, OR SPEAKING AFTER RECEIVING TREATMENT WITH BOTOX, CONTACT YOUR DOCTOR IMMEDIATELY.
If you experiencehives, inflammationincluding inflammation of the face or throat, wheezing, feeling of faintingor shortness of breath, contact your doctor immediately.
Adverse effects are classified into the following categories, depending on the frequency with which they occur:
Very common | May affect more than 1 person in 10 |
Common | May affect up to 1 in 10 people |
Uncommon | May affect up to 1 in 100 people |
Rare | May affect up to 1 in 1,000 people |
Very rare | May affect less than 1 person in 10,000 |
Not known | Cannot be estimated from the available data |
The following are adverse effects that vary depending on the part of the body where BOTOX is injected. If any of the adverse effects worsen, or if you experience any adverse effect that does not appear in this leaflet, please inform your doctor or pharmacist.
Injections in children with persistent muscle spasms in the ankle and foot
Common | Rash, walking problems, stretching or tearing of ligaments, superficial skin wound, pain at the injection site |
Uncommon | Muscle weakness |
Some rare cases of death have been spontaneously reported, sometimes associated with aspiration pneumonia in children with severe cerebral palsy after treatment with BOTOX.
Injections in the wrist and hand of adult patients who have had a stroke
Common | Pain in the hand and fingers, nausea, inflammation of the limbs such as hands or feet, fatigue, muscle weakness |
Injections in the ankle and foot of adult patients who have had a stroke
Common | Rash, joint pain or inflammation, muscle stiffness or pain, muscle weakness, inflammation of the limbs such as hands or feet, falls. |
Very common | Eyelid drooping |
Common | Localized damage to the cornea (transparent surface that covers the front of the eye), difficulty closing the eye completely, dry eyes, sensitivity to light, eye irritation, excessive tearing, bruising under the skin, skin irritation, facial swelling |
Uncommon | Dizziness, facial muscle weakness, drooping of the muscles on one side of the face, corneal inflammation (transparent surface that covers the front of the eye), abnormal rotation of the eyelids outward or inward, double vision, vision problems, blurred vision, rash, fatigue |
Rare | Swelling of the eyelid |
Very rare | Ulcer, damage to the cornea (transparent surface that covers the front of the eye); |
Injections in the neck and shoulders
Very common | Difficulty swallowing, muscle weakness, pain |
Common | Inflammation and irritation inside the nose (rhinitis), congested or runny nose, cough, sore throat, itching or irritation in the throat, dizziness, increased muscle tension, decreased skin sensitivity, drowsiness, headache, dry mouth, nausea, muscle pain or stiffness, feeling of weakness, flu-like syndrome, general malaise |
Uncommon | Double vision, fever, eyelid drooping, difficulty breathing, voice changes. |
Injections in the head and neck for the treatment of headache in patients with chronic migraine
Common | Headache, migraine, and worsening of migraine, facial muscle weakness, eyelid drooping, rash, itching, neck pain, muscle pain, muscle spasm, muscle stiffness, muscle tightness, muscle weakness, pain at the injection site |
Uncommon | Difficulty swallowing, skin pain, jaw pain. |
Not known | Mephisto sign (elevation of the outer part of the eyebrows) |
Injections in the bladder wall for urinary incontinence due to overactive bladder
Very common | Urinary tract infection, painful urination after injection* |
Common | Presence of bacteria in the urine, inability to empty the bladder (urinary retention), incomplete emptying of the bladder, frequent urination during the day, white blood cells in the urine, hematuria (blood in the urine) after injection** |
* This adverse effect is related solely to the injection procedure.
Common | Urinary tract infection, painful urination after injection*, pain in the urethra (the duct that carries urine from the urinary bladder to the outside of the body)*, abdominal pain, lower abdominal pain. |
Injections in the bladder wall of adult patients with urinary incontinence due to bladder problems associated with spinal cord injury or multiple sclerosis
Very common | Urinary tract infection, inability to empty the bladder (urinary retention) |
Common | Difficulty sleeping (insomnia), constipation, muscle weakness, muscle spasm, hematuria (blood in the urine) after injection*, painful urination after injection*, bladder diverticulum (bulge in the bladder wall), fatigue, walking problems, possible uncontrolled reflex reaction of your body (e.g., excessive sweating, pulsating headache, or increased heart rate) around the time of injection (autonomic dysreflexia)*, fall |
*Some of these common adverse effects may be related to the injection procedure.
Very common | Presence of bacteria in the urine |
Common | Urinary tract infection, white blood cells in the urine, blood in the urine after injection, pain in the bladder after injection.* |
*This adverse effect is related solely to the injection procedure.
Injections for excessive sweating in the armpits
Very common | Pain at the injection site |
Common | Headache, tingling, flushing, increased sweating in areas other than the armpits, abnormal skin odor, itching, appearance of lumps under the skin, hair loss, pain in the limbs, such as hands and fingers, pain, reactions, and inflammation, redness, or burning and increased sensitivity at the injection site, general weakness. |
Uncommon | Nausea, muscle weakness, feeling of weakness, muscle pain, joint problems |
The following list describes additional adverse effectsreported for BOTOX, in some disease, since it has been marketed:
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep out of sight and reach of children.
Your doctor should not use BOTOX after the expiration date that appears on the packaging after "EXP". The expiration date is the last day of the month indicated.
Store in the refrigerator (2°C to 8°C) or store in the freezer (-5°C to -20°C).
After preparing the solution, it is recommended to use it immediately; however, it can be stored for up to 24 hours in the refrigerator (2°C to 8°C).
Composition of BOTOX
Appearance of the Product and Container Content
BOTOX is presented as a fine white powder that may be difficult to see at the bottom of a transparent glass vial. Before injection, the product must be dissolved in a normal saline solution without preservatives (sodium chloride 0.9% injectable solution). Each container contains 1, 2, 3, or 6 vials. Additionally, the 50 and 100 Allergan Units of botulinum toxin type A formats may also be presented in containers of 10 vials.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
AbbVie Spain, S.L.U.
Avenida de Burgos 91,
28050 Madrid, Spain
Manufacturer:
Allergan Pharmaceuticals Ireland
Castlebar Road
County Mayo
Ireland
Or
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
Date of the Last Revision of this Prospectus:April 2024
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The following information is exclusively for medical and healthcare personnel:
Please refer to the Technical Sheet for complete prescription information for BOTOX.
The Units of botulinum toxinare not interchangeable from one product to another. The recommended doses in Allergan Units are different from other products with botulinum toxin.
BOTOX should only be administered by doctors with the appropriate qualification and experience in treatment and the use of the required instrumentation.
Chronic migraine should be diagnosed and BOTOX should be administered exclusively under the supervision of neurologists who are experts in the treatment of chronic migraine.
BOTOX is indicated for the treatment of: focal spasticity of the ankle and foot in pediatric patients, two years of age or older; focal spasticity of the wrist and hand secondary to a stroke in adults; focal spasticity of the ankle and foot secondary to a stroke in adults; blepharospasm, hemifacial spasm, and associated focal dystonias; cervical dystonia (spasmodic torticollis); relief of symptoms in adults who meet the criteria for chronic migraine (headaches on ≥ 15 days per month, of which at least eight days correspond to migraine), in patients who have not responded adequately or are intolerant to migraine prophylactic medications; idiopathic overactive bladder with symptoms of urinary incontinence, urgency, and frequency in adult patients who have not responded adequately or are intolerant to anticholinergic medications; urinary incontinence in adults with neurogenic detrusor overactivity due to subcervical spinal cord injury or multiple sclerosis and severe and persistent primary axillary hyperhidrosis that interferes with daily activities and is resistant to topical treatment.
The safety and efficacy of BOTOX have not been established in indications for the pediatric population other than those described in section 4.1 of the Technical Sheet. No dosage recommendation can be made for indications other than infantile focal spasticity associated with cerebral palsy. The available data per indication are described in sections 4.2, 4.4, 4.8, and 5.1 of the Technical Sheet, as shown in the following table.
| 12 years (see sections 4.4 and 4.8) |
| 12 years (see sections 4.4 and 4.8) |
| 2 years (see sections 4.2, 4.4, and 4.8) |
| 12 years (limited experience in adolescents between 12 and 17 years of age, see sections 4.4, 4.8, and 5.1) |
| 5-17 years (see sections 4.8 and 5.1) |
| 12-17 years (see sections 4.8 and 5.1) |
No specific dose adjustment is required for elderly patients. The initial dosage should start with the lowest recommended dose for each indication. For repeated injections, the lowest effective dose with the longest clinically indicated interval between injections is recommended. Patients of advanced age with significant medical history and concomitant medication should be treated with caution.
Generally, optimal dose levels and the number of injection points per muscle have not been established for all indications. In these cases, the doctor should establish an individual treatment regimen. The optimal dose levels should be determined by individual adjustment, but the maximum recommended dose should not be exceeded. As with any pharmacological treatment, the initial dose in a new patient should be the minimum effective dose.
Dosage and Method of Administration (please refer to sections 4.2 and 4.4 of the Technical Sheet for more information).
Focal Spasticity of the Lower Limb in Pediatric Patients
The recommended dose for treating infantile lower limb spasticity is 4 Units/kg to 8 Units/kg of body weight or 300U, whichever is lower, divided among the affected muscles. When treating both lower limbs, the total dose should not exceed 10 Units/kg of body weight or 340 Units, in an interval of 12 weeks.
Muscles Injected | BOTOX 4 Units/kg* (Maximum Units per Muscle) | BOTOX 8 Units/kg** (Maximum Units per Muscle) | Number of Injection Points |
Ankle Muscles Gastrocnemius medial head | 1 Unit/kg (37.5 Units) | 2 Units/kg (75 Units) | 2 |
Gastrocnemius lateral head | 1 Unit/kg (37.5 Units) | 2 Units/kg (75 Units) | 2 |
Soleus | 1 Unit/kg (37.5 Units) | 2 Units/kg (75 Units) | 2 |
Tibial posterior | 1 Unit/kg (37.5 Units) | 2 Units/kg (75 Units) | 2 |
** did not exceed a total dose of 300 Units
Focal Spasticity of the Upper and Lower Limb Secondary to a Stroke:
BOTOX is a treatment for focal spasticity that has only been studied in association with usual treatment regimens and is not indicated as a substitute for these therapeutic modalities. It is likely that BOTOX will not be effective in improving the range of motion in a joint affected by a fixed contracture.
Focal Spasticity of the Upper Limb Secondary to a Stroke:
Muscle | Recommended Dose; Number of Injection Points |
Forearm Pronator quadratus | 10-50 Units; 1 point |
Wrist Radial flexor of the wrist Ulnar flexor of the wrist | 15-60 Units; 1-2 points 10-50 Units; 1-2 points |
Fingers of the hand/hand Deep flexor of the fingers Superficial flexor of the fingers Lumbricals* Interosseous* | 15-50 Units; 1-2 points 15-50 Units; 1-2 points 5-10 Units; 1 point 5-10 Units; 1 point |
Thumb Thumb adductor Long flexor of the thumb Short flexor of the thumb Thumb opponent | 20 Units; 1-2 points 20 Units; 1-2 points 5-25 Units; 1 point 5-25 Units; 1 point |
*When injecting the lumbricals and/or interosseous, the maximum recommended dose is 50 U per hand.
The recommended dose for the treatment of upper limb spasticity in adults is up to 240 Units divided among the affected muscles as indicated in the table above. The maximum dose in a treatment is 240 Units.
The exact dose and number of injection points must be individualized based on the size, number, and location of the affected muscles, the severity of the spasticity, the presence of muscle weakness, and the patient's previous response to treatment.
Focal Spasticity of the Lower Limb Secondary to a Stroke:
Muscle | Recommended Dose Total Dose; Number of Injection Points |
Gastrocnemius Medial head Lateral head | 75 Units; 3 points 75 Units; 3 points |
Soleus | 75 Units; 3 points |
Tibial posterior | 75 Units; 3 points |
Long flexor of the big toe | 50 Units; 2 points |
Long flexor of the fingers | 50 Units; 2 points |
Short flexor of the fingers | 25 Units; 1 point |
The recommended dose for the treatment of lower limb spasticity in adults affecting the ankle and foot is 300 Units to 400 Units divided among up to 6 muscles.
Blepharospasm/Hemifacial Spasm:
Muscles | Dose Selection |
Medial and lateral orbicularis oculi and lateral orbicularis oculi of the lower eyelid. Additional points in the eyebrow area, such as the lateral orbicularis and the upper face area, may be injected if spasms in this area interfere with vision. Patients with hemifacial spasm or seventh cranial nerve disorders should be treated as for unilateral blepharospasm, injecting other affected facial muscles (e.g., zygomatic major or orbicularis oris) as necessary. | 1.25-2.5 Units in the medial and lateral orbicularis oculi and lateral orbicularis oculi of the lower eyelid. The initial dose should not exceed 25 Units per eye. The total dose should not exceed 100 Units every 12 weeks. |
A reduction in blinking after injection of botulinum toxin in the orbicularis muscle may cause corneal pathology. Corneal sensitivity should be carefully evaluated in previously operated eyes, avoiding injection in the lower eyelid area to avoid ectropion, and using vigorous treatment of any epithelial defect. This may require protective drops, ointments, soft contact lenses, or eye closure with a patch or other means.
Cervical Dystonia:
Muscles | Dose Selection |
Sternocleidomastoid, levator scapulae, scalene, splenius capitis, semispinalis, longus colli, and/or trapezius. | No more than 50 Units should be injected per injection point. No more than 100 Units should be injected into the sternocleidomastoid muscle. No more than 200 Units should be injected in total during the first treatment session, with adjustments in subsequent sessions depending on the initial response. The total dose should not exceed 300 Units in a session. |
The list of muscles is not exhaustive, as any of the muscles responsible for controlling head position may be involved and therefore require treatment.
Chronic Migraine
The recommended dose of reconstituted BOTOX for the treatment of chronic migraine is 155 Units to 195 Units, administered intramuscularly (IM), with a 30-gauge needle and 1.25 cm in length, with injections of 0.1 ml (5 Units), in 31 to 39 points. The injections should be divided into seven specific muscle zones of the head and neck, as specified in the following table. A 2.5 cm needle may be necessary in the neck region for patients with extremely thick neck muscles. With the exception of the procerus muscle, which should be injected at one point (midline), all muscles should be injected on both sides, administering half of the number of injections on the left side of the head and neck, and the other half on the right. If there is one or more predominant locations of pain, more injections can be administered on one or both sides, up to three specific muscle groups (occipital, temporal, and trapezius), up to the maximum dose per muscle indicated in the following table.
Recommended Dose | |
Head and Neck Region | Total Dosage (Number of Pointsa) |
Superciliar or corrugator of the eyebrowsb | 10 Units (2 points) |
Procerus | 5 Units (1 point) |
Frontalb | 20 Units (4 points) |
Temporab | 40 Units (8 points) up to 50 Units (up to 10 points) |
Occipitalb | 30 Units (6 points) up to 40 Units (up to 8 points) |
Cervical paravertebral muscle groupb | 20 Units (4 points) |
Trapeziusb | 30 Units (6 points) up to 50 Units (up to 10 points) |
Total Dose Range: | 155 Unitsto 195 Units 31 to 39 points |
aOne IM injection point = 0.1 ml = 5 Units of BOTOX
bDose distributed on both sides.
Urinary Incontinence due to Overactive Bladder
The recommended dose is 100 Units of BOTOX in injections of 0.5 ml (5 Units) administered in 20 points of the detrusor, avoiding the trigone and base.
Urinary Incontinence due to Neurogenic Detrusor Overactivity:
The recommended dose is 200 Units of BOTOX in injections of 1 ml (approximately 6.7 Units) administered in 30 points of the detrusor, avoiding the trigone and base.
Primary Axillary Hyperhidrosis:
Injection Sites | Dose Selection |
Multiple sites separated by approximately 1-2 centimeters within the hyperhidrotic area of each axilla | Doses other than 50 Units per axilla have not been studied and therefore cannot be recommended. |
A medical history and physical examination, along with any additional specific complementary tests that may be required, should be performed to exclude potential causes of secondary hyperhidrosis (e.g., hyperthyroidism, pheochromocytoma). This will avoid symptomatic treatment of hyperhidrosis without diagnosis and/or treatment of the underlying disease.
For all Indications:
Adverse effects related to the distant spread of the toxin from the site of administration have been reported, which sometimes caused death, and in some cases were associated with dysphagia, pneumonia, and/or significant weakness. The symptoms are consistent with the mechanism of action of the botulinum toxin and have been reported from hours to weeks after injection. The risk of symptoms is probably greater in patients with underlying conditions and comorbidities that may predispose them to these symptoms, including children and adults treated for spasticity, and those being treated with high doses.
Patients treated with therapeutic doses may also experience excessive muscle weakness.
Pneumothorax associated with the injection procedure has been reported after administration of BOTOX near the thorax. Caution is needed when injecting near the lung, particularly the apices or other vulnerable anatomical structures.
Severe adverse reactions, including fatal outcomes, have been reported in patients who received BOTOX injections off-label, directly into the salivary glands, oropharyngeal region, and lingual, esophagus, and stomach. Some patients had dysphagia or significant weakness prior to treatment.
Rarely, cases of death have been reported, sometimes associated with aspiration pneumonia in children with severe cerebral palsy after treatment with botulinum toxin, including off-label use (e.g., in the neck area). Extreme caution should be exercised when treating pediatric patients with significant neurological weakness, dysphagia, or a recent history of aspiration pneumonia or pulmonary disease. Treatment should be administered to patients with underlying poor health only if the potential benefit to the individual patient outweighs the risks.
Exceptionally, an anaphylactic reaction may occur after injection of botulinum toxin. Therefore, epinephrine (adrenaline) and other anti-anaphylactic measures should be available.
Consult the BOTOX Technical Sheet for complete information.
In case of treatment failure after the first treatment session, for example, absence of significant clinical improvement one month after injection, the following actions should be taken:
Note: The translation provided is a complete translation of the original text, maintaining all HTML structure, tags, and formatting exactly as provided, and preserving all medical terminology accuracy in English.
In the event of treatment failure or diminished effect after repeated injections, alternative treatment methods should be used.
Reconstitution of the drug:
If different sizes of BOTOX vials are used as part of an injection procedure, care should be taken to use the correct amount of diluent when reconstituting a particular number of units per 0.1 ml. The amount of diluent varies between BOTOX 50 Units Allergan, BOTOX 100 Units Allergan, and BOTOX 200 Units Allergan. Each syringe should be labeled appropriately.
It is good practice to carry out the reconstitution of the vial and the preparation of the syringe on plastic-coated paper towels to collect any possible spilled material.
BOTOX should be reconstituted only with sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution). Aspirate the appropriate amount of diluent (see instructions or dilution table below) with a syringe.
Dilution instructions for the treatment of urinary incontinence due to overactive bladder:
It is recommended to use a vial of 100 Units or two vials of 50 Units as they are more convenient for reconstitution.
If you need to use a vial of 200 Units, reconstitute a vial of 200 Unitsof BOTOX with 8 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) and gently mix the vial. Withdraw 4 ml from the vial into a 10 ml syringe. Complete the reconstitution by adding 6 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) to the 10 ml syringe, and gently mix. This will yield a 10 ml syringe containing a total of 100 Units of reconstituted BOTOX. Use immediately after reconstitution in the syringe. Discard unused saline solution.
Reconstitute a vial of 100 Unitsof BOTOX with 10 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) and gently mix. Withdraw the 10 ml from the vial into a 10 ml syringe. This will yield a 10 ml syringe containing a total of 100 Units of reconstituted BOTOX. Use immediately after reconstitution in the syringe. Discard unused saline solution.
Reconstitute two vials of 50 Unitsof BOTOX, each with 5 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) and gently mix each vial. Withdraw the 5 ml from each vial into a single 10 ml syringe. This will yield a single 10 ml syringe containing a total of 100 Units of reconstituted BOTOX. Use immediately after reconstitution in the syringe. Discard unused saline solution.
This product is for single use, and any unused reconstituted product should be discarded.
Dilution instructions for the treatment of urinary incontinence due to neurogenic detrusor overactivity:
It is recommended to use a vial of 200 Units or two vials of 100 Units as they are more convenient for reconstitution.
Reconstitute a vial of 200 Unitsof BOTOX with 6 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) and gently mix the vial. Withdraw 2 ml from the vial into each of three 10 ml syringes. Complete the reconstitution by adding 8 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) to each of the 10 ml syringes, and gently mix. This will yield three 10 ml syringes containing a total of 200 Units of reconstituted BOTOX. Use immediately after reconstitution in the syringe. Discard unused saline solution.
Reconstitute two vials of 100 Unitsof BOTOX, each with 6 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) and gently mix the vials. Withdraw 4 ml from each vial into each of two 10 ml syringes. Withdraw the remaining 2 ml from each vial into a third 10 ml syringe. Complete the reconstitution by adding 6 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) to each of the 10 ml syringes, and gently mix. This will yield three 10 ml syringes containing a total of 200 Units of reconstituted BOTOX. Use immediately after reconstitution in the syringe. Discard unused saline solution.
If you need to use vials of 50 Units, reconstitute four vials of 50 Unitsof BOTOX, each with 3 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) and gently mix the vials. Withdraw 3 ml from the first vial and 1 ml from the second into a 10 ml syringe. Withdraw 3 ml from the third vial and 1 ml from the fourth into a second 10 ml syringe. Withdraw the remaining 2 ml from the second and fourth vials into a third 10 ml syringe. Complete the reconstitution by adding 6 ml of sterile normal saline solution without preservatives (0.9% sodium chloride injectable solution) to each of the 10 ml syringes, and gently mix. This will yield three 10 ml syringes containing a total of 200 Units of reconstituted BOTOX. Use immediately after reconstitution in the syringe. Discard unused saline solution.
Dilution table for BOTOX 50, 100, and 200 Units Allergan vials for the remaining indications:
Vial of 50 Units | Vial of 100 Units | Vial of 200 Units | |
Resulting dose (Units per 0.1 ml) | Amount of diluent (sterile normal saline solution without preservatives - 0.9% sodium chloride injectable solution) in a vial of 50 Units | Amount of diluent (sterile normal saline solution without preservatives - 0.9% sodium chloride injectable solution) in a vial of 100 Units | Amount of diluent (sterile normal saline solution without preservatives - 0.9% sodium chloride injectable solution) in a vial of 200 Units |
20 Units | 0.25 ml | 0.5 ml | 1 ml |
10 Units | 0.5 ml | 1 ml | 2 ml |
5 Units | 1 ml | 2 ml | 4 ml |
2.5 Units | 2 ml | 4 ml | 8 ml |
1.25 Units | 4 ml | 8 ml | N/A |
This product is for single use, and any unused solution should be discarded.
Since BOTOX is denatured by violent agitation or bubble formation, the solvent should be injected into the vial gently. Discard the vial if the vacuum does not draw the solvent into the vial. Reconstituted BOTOX is a clear, colorless to slightly yellowish solution, free of particles. Before use, it will be visually checked that the reconstituted solution is clear and free of particles. Once reconstituted in the vial, BOTOX can be stored in the refrigerator (2°C-8°C) for up to 24 hours before use. If it is further diluted in a syringe for intradetrusor injection, it should be used immediately.
Potency studies have shown that the product can be stored for up to 5 days at 2°C-8°C after reconstitution.
From a microbiological point of view, the product should be used immediately. If it is not used immediately, the storage conditions after reconstitution and prior to use are the responsibility of the user and should not exceed 24 hours at 2°C-8°C, unless the reconstitution, dilution, etc. have taken place in controlled and validated aseptic conditions. The date and time of reconstitution should be noted on the space provided on the label.
Procedure for the safe disposal of vials, syringes, and used materials
Medicines should not be disposed of via wastewater or household waste. For safe disposal, unused vials should be reconstituted with a small amount of water and then autoclaved. All used vials and syringes and spilled material, etc. should be autoclaved, or the residual BOTOX can be inactivated with a diluted solution of hypochlorite (0.5%) for 5 minutes.
Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Product identification
In order to verify that the BOTOX product is from Allergan, please look for two transparent warranty seals containing the Allergan silver and translucent logo, which are located on the top and bottom of the BOTOX box flaps, and a holographic film on the vial label. To view this film, examine the vial under a desk lamp or a fluorescent light source. By rotating the vial back and forth between your fingers, look for the horizontal lines of rainbow color on the label and confirm that the name "Allergan" appears within the rainbow lines.
Do not use the product and contact your local AbbVie office if:
Additionally, two removable stickers have been added to the label of the BOTOX vial, which include the batch number and expiration date of the product. These stickers can be removed and attached to the patient's record for traceability purposes. Note that once the stickers are removed from the label of the BOTOX vial, the word "Used" will appear, ensuring that the product is authentic BOTOX manufactured by Allergan.